Is a clinical research site still profitable? Margins, costs, and where money leaks

What does the data say about site finances?

• 38% of sites saw profits decline in 2023, and 37% have under $1 million in gross revenue (SCRS).
• About 82% of sites reported operating costs rising 6% or more in 2024, over half saw double digit increases, salaries were the main driver for about 69%, and 41.2% said they could not offset the increase (Bourne Partners, citing SCRS).
• 74% of sites say their top need is more robust sponsor budgets (SCRS).

Where does the money leak?

1. Screen failures: 88% say they are not sufficiently covered (SCRS), and 42% say screen failure terms never or rarely cover actual screen fails (SCRS).
2. Recruitment: 53% of sites regularly pay for it from their own funds (SCRS).
3. Studies that never fill: in a typical trial 11% of sites enroll zero patients and 37% under enroll (Tufts CSDD). Startup work is spent either way; revenue follows patients.
4. Unbilled work: prescreening, extra visits, and amendments that never make it onto an invoice.

What margins do healthy sites aim for?

Buyers of research sites treat EBITDA margins of 25% to 50% as a sign of operational discipline, according to an investment bank that advises site sales (Objective IBV). Treat that as a buyer's benchmark, not a typical result.

What protects profit?

• Negotiating screen failure, startup, and recruitment lines. See the budget negotiation checklist.
• Knowing what one enrolled patient is worth per study. Try the revenue per patient calculator.
• Declining studies the site cannot fill.
• Building patient sources that deliver qualified patients, so enrollment, and revenue, actually happens.

Where do referrals fit?

The fastest way to improve a site's economics is to enroll more of the studies it already has. Patients referred by physicians who know their history tend to arrive prequalified, which also cuts unpaid screen failures.